– The U.S. Centers for Disease Control and Prevention (CDC) on Wednesday reported 2,624,873 cases of new coronavirus, an increase of 43,644 cases from its previous count, and said that the number of deaths had risen by 560 to 127,299. The CDC reported its tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, as of 4 pm ET on June 30 compared with its previous report a day earlier.…"U.S. CDC reports 2,624,873 coronavirus cases"
SEOUL/BERLIN/LONDON – Some governments in Europe and Asia said on Wednesday they have enough of Gilead’s COVID-19 anti-viral remdesivir for now despite fears of shortages since the U.S. drugmaker pledged most output to its home market for the next three months. The pharmaceutical company’s move stirred the global debate about equitable access to drugs and brought concerns about accessibility, especially in regions where coronavirus rates are still high or there have been new outbreaks. Remdesivir…"World takes stock of COVID-19 drug remdesivir after U.S. snaps up supplies"
SAO PAULO – A potential coronavirus vaccine developed by China’s Sinovac will be tested in Brazil by 12 research centers in 6 Brazilian states, the governor of Sao Paulo state, Joao Doria, said on Wednesday, adding the trials still need to be approved by local health vigilance agency Anvisa. The study – first announced on June 11 – is led by Instituto Butantan, a research center funded by the state of Sao Paulo. The center’s…"Brazil to test Sinovac’s potential vaccine against COVID-19 in six states"
JOHANNESBURG – Anti-vaccine protesters took to the streets in Johannesburg on Wednesday to voice their concern over Africa’s first human trials for a potential coronavirus vaccine. Last Wednesday, the University of the Witwatersrand in partnership with Oxford University rolled out South Africa’s first clinical trial, which will consist of 2,000 volunteers. The involvement of South Africa in vaccine trials is intended to ensure the continent will have access to an affordable vaccine and not be…"‘We are not guinea pigs,’ say South African anti-vaccine protesters"
LONDON – Britain has adequate supplies of Gilead’s remdesivir for emergency use to treat hospitalised COVID-19 patients, England’s deputy chief medical officer said on Wednesday, though he warned of potential difficulties securing future supplies. Gilead said this week it had allocated nearly all of its supply of the antiviral to the United States over the next three months, stirring concerns about availability elsewhere, particularly in regions where infection rates are still high. “I judge us…"UK emergency remdesivir supplies adequate to treat COVID-19, official says"
LONDON – A leading scientist behind the University of Oxford’s potential COVID-19 vaccine said on Wednesday the team has seen the right sort of immune response in trials, which have entered the Phase III clinical stage. Speaking at a parliamentary hearing, Sarah Gilbert, professor of vaccinology at the university, said the trial has enrolled 8,000 volunteers for the Phase III of its trial into the vaccine, AZD1222, which was licensed to AstraZeneca. She said she…"Oxford University has seen ‘right sort of immune response’ in potential COVID-19 vaccine trial: scientist"
– A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday. The drug is one of 17 being tested on humans in a frantic global race to find a vaccine the world is counting on to end a pandemic that has killed more than half a million so far. The following rivals…"Factbox: COVID-19 vaccine candidates with early human-trial data"
FRANKFURT – A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday. The drug is one of 17 being tested on humans in a frantic global race to find a vaccine the world is counting on to end a pandemic that has infected 10.5 million people and killed more than half a…"BioNTech and Pfizer’s COVID-19 vaccine shows potential in human trial"
– The U.S. Food and Drug Administration has approved more than 30 new drugs since January. So far, five medicines have seen their commercial launches delayed by manufacturers until later in the year or 2021 because of the COVID-19 pandemic. Here are the drugs that have been delayed: PALFORZIA Aimmune Therapeutics Inc paused the launch of the first peanut allergy treatment to be approved by U.S. regulators until later this year because of the widespread…"New drug launches stalled by COVID-19 pandemic"
– Treatments for peanut allergy and Parkinson’s disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a review of filings and interviews with executives show. The Food and Drug Administration (FDA) has approved more than 30 new medicines since January, but at least five drugmakers including Bristol Myers Squibb , Sanofi , Neurocrine Biosciences , Endo Pharmaceuticals and Aimmune have changed their launch…"From Parkinson’s to peanut allergy, pandemic puts brakes on new drugs"